<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04852666</url>
  </required_header>
  <id_info>
    <org_study_id>19-0273</org_study_id>
    <secondary_id>PaCR-2017C2-8172-IC</secondary_id>
    <nct_id>NCT04852666</nct_id>
  </id_info>
  <brief_title>Comparative Effectiveness of Biologics or Small Molecule Therapies in Inflammatory Bowel Disease (IBD)</brief_title>
  <acronym>COMPARE</acronym>
  <official_title>Comparative Effectiveness of Biologics or Small Molecule Therapies After Failure of Anti-TNF Treatment in Patients With Crohn's Disease and Ulcerative Colitis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of North Carolina, Chapel Hill</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Patient-Centered Outcomes Research Institute</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Crohn's &amp; Colitis Foundation</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of North Carolina, Chapel Hill</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to assess effectiveness of vedolizumab versus ustekinumab in&#xD;
      patients with Crohn's disease and vedolizumab versus tofacitinib in patients with ulcerative&#xD;
      colitis, after non-response to anti-tumor necrosis factor (TNF) medications, using data from&#xD;
      two existing cohorts.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study is a secondary analysis using data from participants in the IBD Partners and&#xD;
      SPARC-IBD cohorts. Data received from IBD Partners consists of patient-reported outcomes&#xD;
      gathered via online surveys (baseline and 6-month follow-ups). Data received from SPARC-IBD&#xD;
      consists of patient-reported outcomes gathered via surveys (baseline and follow-ups) as well&#xD;
      as data from clinical records.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Enrolling by invitation</overall_status>
  <start_date type="Actual">July 25, 2019</start_date>
  <completion_date type="Anticipated">December 2021</completion_date>
  <primary_completion_date type="Anticipated">December 2021</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>PROMIS measures of pain interference</measure>
    <time_frame>4-10 months after medication initiation</time_frame>
    <description>NIH Patient Reported Outcome Measurement Information System (PROMIS) measures of Pain Interference. PROMIS scores can range from 0 to 100; scales are calibrated using a T-score metric with a mean of 50 and standard deviation of 10. A higher score indicates more pain interference.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>PROMIS measures of fatigue</measure>
    <time_frame>4-10 months after medication initiation</time_frame>
    <description>NIH Patient Reported Outcome Measurement Information System (PROMIS) measures of Fatigue. PROMIS scores can range from 0 to 100; scales are calibrated using a T-score metric with a mean of 50 and standard deviation of 10. A higher score indicates more fatigue.</description>
  </primary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">900</enrollment>
  <condition>Crohn's Disease</condition>
  <condition>Ulcerative Colitis</condition>
  <arm_group>
    <arm_group_label>IBD Partners cohort</arm_group_label>
    <description>IBD Partners is an internet-based cohort study of patients with Crohn's disease (CD) and ulcerative colitis (UC). It is coordinated by the University of North Carolina School of Medicine in conjunction with the Crohn's &amp; Colitis Foundation. There is no intervention for this study.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>SPARC-IBD cohort</arm_group_label>
    <description>SPARC-IBD is a multi-center cohort study of patients with Crohn's disease (CD) and ulcerative colitis (UC). It is coordinated by the Crohn's &amp; Colitis Foundation. There is no intervention for this study.</description>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        Population: participants in IBD Partners or SPARC cohort.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  age greater than or equal to 18;&#xD;
&#xD;
          -  diagnosis of CD or UC (as reported by participant for IBD Partners and/or physician&#xD;
             for SPARC);&#xD;
&#xD;
          -  initiated vedolizumab or ustekinumab for CD, or initiated vedolizumab or tofacitinib&#xD;
             for UC; treated with anti-TNF prior to vedolizumab/ustekinumab/tofacitinib.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  less than 18 years of age&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Michael Kappelman, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of North Carolina, Chapel Hill</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Crohn's &amp; Colitis Foundation</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10017</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of North Carolina</name>
      <address>
        <city>Chapel Hill</city>
        <state>North Carolina</state>
        <zip>27599-7555</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2021</verification_date>
  <study_first_submitted>April 16, 2021</study_first_submitted>
  <study_first_submitted_qc>April 16, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">April 21, 2021</study_first_posted>
  <last_update_submitted>April 16, 2021</last_update_submitted>
  <last_update_submitted_qc>April 16, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">April 21, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Crohn Disease</mesh_term>
    <mesh_term>Colitis</mesh_term>
    <mesh_term>Colitis, Ulcerative</mesh_term>
    <mesh_term>Ulcer</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

